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Application of surface enhanced Raman scattering
to the solution based detection of a popular legal
high, 5,6-methylenedioxy-2-aminoindane (MDAIQ1 )†
Samuel Mabbott,a,b Omar Alharbi,a Kate Grovesa and Royston GoodacreQ2Q3 a
The ever increasing numbers and users of designer drugs means that analytical techniques have to evolve
constantly to facilitate their identiﬁcation and detection. We report that surface enhanced Raman scatter-
ing (SERS) oﬀers a relatively fast and inexpensive method for the detection of MDAI at low concentrations.
Careful optimisation of the silver sol, and salt concentrations was undertaken to ensure the SERS analysis
was both reproducible and sensitive. The optimised system demonstrated acceptable peak variations of
less than 15% RSD and resulted in a detection limit of just 8 ppm (5.4 × 10−5 M).
Introduction
Recently there has been raised concern over the increased rec-
reational usage of legal highs.1–3 These synthetic derivatives of
banned substances such as MDMA and amphetamines have
flooded the drugs market, often the derivatives provide a
cheaper alternative to illegal substances. Legal highs have the
potential to cause major health risks, due to little knowledge
of the chemicals they contain and lack of information about
human consumption. Furthermore, whilst short-term side
eﬀects are easily documented little is known about the eﬀects
of their long-term usage. Accessibility of the drugs over the
internet and in so called ‘headshops’, also makes them an
attractive option for users, although sale of the drugs is nor-
mally considered illegal under the medicines legislation act.22
This is why many sellers of the ‘highs’ often advertise them as
bath salts or plant food (not for human consumption). In the
UK alone it has been reported that 150 new legal highs were in
circulation in the three years between 2010 and 2013.24
Popular ‘highs’ being sold over the internet include 5-IAI (5-
iodo-2-aminoindane),4 Benzofury (6-(2-aminopropyl)benzo-
furan)5 and MDAI (5,6-methylenedioxy-2-aminoindane)6,7 to
name but a few. However, it is the latter of these drugs, MDAI
(Fig. 1) which is of concern to this work. The widespread avail-
ability and recreational use of MDAI is thought to have been
created via the banning of mephedrone, a cathinone deriva-
tive,8,9 which had caught the attention of the UK media
towards the end of 2009.10,11 Due to the growth in the number
of users and documented ill-eﬀects, the substance was conse-
quently categorised as a class B drug along with other cathi-
none derivatives in April 2010.12 Nichols at Purdue University
first synthesised MDAI in 1990,13 the structural basis is similar
to that of 3,4-methylenedioxy-N-methylamphetamine (MDMA)
with the only diﬀerence between the two being that the
methylpropan-2-amine moiety of MDMA is replaced with a
2-aminoindane group. MDAI has been shown to have a indis-
tinguishable pharmacology to MDMA (Fig. 1) whose primary
mechanism is to act as a selective serotonin releasing
agent.14,15 It is therefore evident that like most amphetamines
MDAI is taken for its entactogenic eﬀects, which include
increased levels of intimacy, consciousness and euphoria, but
these eﬀects often contradict online blogs written by the drugs
users who demonstrate mixed reviews about the drug’s eﬀect.8
Most seriously however, it is believed that the first death
caused by an MDAI overdose was recorded in the Isle of Man
on the 15th of April 2011.16 The development and optimisation
of new and existing laboratory analytical methods is essential
in order to remain up-to-date with the rapid changes in drugs
culture.17 However, little analytical work to detect and estab-
lish the limit of detection of MDAI has been carried out. There
Fig. 1 The structure of MDAI with numbers for NMR assignment and
the amphetamine MDMA.
†Electronic supplementary information (ESI) available: Raman spectrum of
MDAI powder (Fig. S1) and the SERS spectra of MDAI collected at diﬀerent drug
concentrations (Fig. S2). See DOI: 10.1039/c5an00591d
aManchester Institute of Biotechnology, School of Chemistry, The University of
Manchester, Manchester, M1 7DN, UKQ4
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are very few studies in the literature that report analytical
methods for the detection of MDAI. One article reports on how
microcrystalline analysis of MDAI is capable of establishing a
LOD of 0.2 g L−1,18 whilst another described the use of GC-MS,
NMR and FT-IR for the characterisation of MDAI and other
structural analogues.19 It is therefore evident that much work
is needed in the detection of the synthetic legal high. Raman
spectroscopy is an attractive option for the drugs analysis.
However, whilst it generates a unique spectrum of interrogated
analytes, the inherent lack of sensitivity and fluorescence
based problem that severely aﬀects its usefulness at detecting
compounds at low concentrations. Both of these issues can be
overcome using SERS (surface enhanced Raman scattering).
Here, the analyte of interest is brought into close proximity to
metal nanoparticles whose plasmon coupling with laser
irradiation is responsible for enhanced Raman scattering
eﬀects which shows a great increase in analyte detection sensi-
tivity over conventional Raman.20,21 Optimisation of SERS
systems is crucial to ensure that the reproducibility of signal
and low detection limits are achieved. SERS analyses in solu-
tion are often highly dynamic so control of variables can often
be diﬃcult. The main component of a solution based system
are the metal colloid, aggregating agent and analyte, all of
which need to be optimised. Here it is demonstrated that the
optimisation of a SERS system can be accomplished using a
systematic approach for the rapid detection of MDAI at very
low concentrations. The portability of Raman instruments
coupled with the added sensitivity of SERS makes this methodo-
logy much more amenable than other analytical techniques
to on-site sampling; that is to say within a club or home
setting.
Experimental
Materials
Silver nitrate (99.9999%) and trisodium citrate were purchased
from Sigma Aldrich (Dorset, U.K.). A 100 mg capsule of MDAI
(5,6-methylenedioxy-2-aminoindane) sold as ‘Sparkle’ was pur-
chased from a ‘headshop’ (Dr Herman’s, Manchester, U.K.).
The drug contained within the capsule had a white flaky
appearance. The purity of the drugs was verified via melting
point tests, mass spectrometry (MS) and nuclear magnetic
resonance spectroscopy (NMR). All solvents used were of
analytical grade and water was HPLC certified.
Methods
Drug purity verification. Although the drug was advertised
as being supplied in 100 mg amounts, the weight of the drug
without the capsule was only 73 mg therefore the analytical
techniques used to verify purity had to be selected carefully.
Both MS and NMR were used to derive the structure of the
drug and to ensure that no other impurities were present. The
melting point tests gaves an accurate idea of the purity due to
the sharpness and temperature at which the sample melted.
The values obtained from these analyses could be directly
compared to the original synthesis values.13
Mass spectrometry. The samples were analysed using
electrospray ionisation mass spectrometry (ESI-MS) operating
in positive mode. Two peaks were identified in the spectrum at
m/z of 161 and 178, relating to MDAI minus the protonated
amine moiety and protonated MDAI respectively.
1H NMR (200 MHz, D2O). δ 6.73, (s, 2, ArH), 5.84 (s, 2, CH2),
4.05 (m, 1, CH), 3.19 (dd, 2, 2 × CH, J = 15.4 Hz, 6.6 Hz), 2.84
(dd, 2, 2 × CH, J = 15.4 Hz, 5.2 Hz), 2.15 (s, 2, NH2).
13C NMR (300 MHz, D2O). Bracketed numbers relate to the
positions of the carbons outlined in Fig. 1.
δ 146.7 (1), 131.9 (2), 105.4 (3), 101.1(6), 52.1 (5), 36.9 (4).
Melting point test
Five replicate melting point tests were carried out on ∼3 mg of
the drug per test. The melting point was sharp and averaged
275 °C only 1 °C lower than the original synthetic value.13
Synthesis of silver colloids
All glassware was cleaned using aqua regia to remove any
residual trace metals. After 1 h of treatment the flasks were
then washed with copious amounts of methanol, dried under
a stream of nitrogen then rinsed with water. To ensure all the
solvents had evaporated, the flasks were placed in a tempera-
ture-controlled oven (60 °C) for 20 min. Silver nanoparticles
were synthesised using the Lee and Meisel method.23 Initially
AgNO3 (90 mg) was dissolved in 500 mL of water and bought
to the boil. Under vigorous stirring a 1% solution of trisodium
citrate (10 mL) was added. The solution/sol was left to boil for
1 h, the formation of nanoparticles was verified when the pre-
viously transparent solution developed a milky green hue. The
method was replicated for the synthesis of five batches of
silver colloid.
UV-visible (UV-vis) absorption/extinction nanoparticle
characterisation
In order to determine the position of the plasmon band λmax it
was essential to characterise the nanoparticles using UV-vis
spectrophotometry. Samples were prepared by combining 1
part silver colloid with 9 parts water. 1 mL of the dilute nano-
particle solution was then pipetted into a quartz cuvette and
inserted into a sample holder of a Thermo Biomate 5 (Thermo
Fisher Scientific Inc., Massachusetts, USA). A spectrum was
collected for each of the 5 colloidal batches. Fig. 2 shows the
typical UV-Vis spectra obtained whilst the table details the λmax
and full width, half maximum (FWHM) for each batch of
colloid.
SERS analyses
Raman spectra were collected using a DeltaNu Advantage
benchtop Raman spectrometer (Intevac inc, California, USA).
The instrument is equipped with a 633 nm HeNe laser with a
power output of 3 mW at sample. Spectra were collected over a
range of 200–3400 cm−1 with a spectral resolution of 10 cm−1.
Solution samples were placed in an 8 mm diameter glass vial
Paper Analyst
2 | Analyst, 2015, 00, 1–8 This journal is © The Royal Society of Chemistry 2015
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
and subjected to laser irradiation once loaded into the sample
cell attachment. The instrument was calibrated to determine
the optimum distance from the laser to the glass vial using
toluene and polystyrene. Raman spectra of the solid MDAI
sample were also taken on the same system but unfortunately
the signal response was a broad and featureless (see an
example spectrum in Fig. S1†). It was due to the lack of
specific vibrational features and strong fluorescent background
that analyses had to be carried out in solution using SERS,
which is known to quench fluorescence and also enhance the
Raman signature.
Optimisation of aggregation
The control of such a dynamic system present in solution
based SERS is essential to ensure maximum reproducibility.
One of the ways of managing reproducibility is to optimise the
aggregation time. Variation in SERS signal can result from
diﬀering batches of colloids therefore 5 batches of silver col-
loids were synthesised and tested along with diﬀering concen-
trations of KNO3 aggregating agent (0.5 M and 1.0 M) with a
set analyte concentration of 500 ppm (2.8 × 10−3 M). Although
many diﬀerent aggregating agents could have been used, pre-
vious experiments carried out in the group found that systems
including KNO3 gave the best SERS response (data not shown).
To reduce any Raman/SERS signal variability as a result of
diﬀering the volume of components, the colloid and analyte
volume were kept at 200 μL and aggregating agent at 50 μL,
resulting in 450 μL of experimental solution being interrogated
in total. The order in which the individual components were
added to the glass vial was also kept constant. Initially the
colloid was added followed by the MDAI solution then the
aggregating agent. To allow time for the nanoparticles and
analytes to equilibrate in solution a 40 min lag phase was
included before the aggregating agent was added. Raman
spectra was collected on each of the samples over a period of
40 min with each spectra generated over a 30 s interrogation
period. This resulted in 80 spectra being collected for each
sample. A total of 10 samples were scrutinized. A definition of
what the proposed optimum aggregation time is and the metho-
dology for its discovery is given in the results and discussion
section.
Reproducibility studies
Once the optimum aggregation time had been established for
each experimental system, replicate sample reproducibility was
tested. In order to do this, samples were made up exactly as
outlined in the aggregation study, whilst varying the time that
the samples were left to aggregate for their identified aggrega-
tion period before collecting a SERS spectrum of the sample
for 30 s. Five replicate samples from each batch of sol at the
diﬀering salt concentrations were used to assess reproducibil-
ity. A total of 50 samples were interrogated (5 replicates × 5 col-
loidal batches × 2 salt concentrations).
Limit of detection (LOD) studies
Once the reproducibility of the SERS systems had been
assessed, the best system was used to evaluate the LOD of the
drug. The drug concentrations analysed ranged from 500 ppm
(2.8 × 10−3 M) to 1 ppm (5.6 × 10−6 M). Five replicate samples
were analysed at each concentration, and as before the opti-
mised aggregation times were used. Analyte concentration did
not aﬀect the optimum aggregation time used.
Results and discussion
Optimisation of aggregation time
Aggregation of nanoparticles is essential to produce ‘hot-spots’
from which the Raman signal of an analyte is enhanced. The
addition of a salt is a common method of inducing aggrega-
tion, however the clustering of nanoparticles needs to be con-
trolled if the enhanced signal is to be reproducible.
The initial challenge was thus to identify the optimum
aggregation. The word optimum in this instance defines the
time at which the SERS signal plateaus, yielding the most
reproducible SERS response The 40 min lag phase introduced
before the addition of an aggregating agent was to allow the
maximum number of MDAI molecules to associate with the
nanoparticles and displace citrate molecules used to stabilise
the metal entities, by doing this it was hoped that little vari-
ation and shifting of the SERS peaks would arise. Spectra gen-
erated on the DeltaNu Raman spectrometer were saved and
exported in a .spc format. Data were analysed using Matlab
version 2011a (The MathWorks, Inc., Natick, Massachusetts,
USA). Once the spectra had been collected from the 10 SERS
systems, the 80 spectra representative of each individual
system were averaged, to elucidate the peak positions. A stag-
gered plot of mean spectra for each of the colloidal batches is
Fig. 2 UV-vis spectrophotometry results for the ﬁve silver colloidal
batches.
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shown in Fig. 3 (A shows spectra generated when 0.5 M aggre-
gating agent was used and B shows spectra generated when 1.0 M
aggregating agent was used). Every single peak that was
present in the mean spectra was assigned a maximum and
given defined start and end points (minimums). The peaks
were then extracted and baseline corrected using an asym-
metric least squares method. Although at this stage in the ana-
lysis it was not possible to clarify whether the bands present
were the result of citrate scattering, MDAI scattering or in fact
a combination of both.
Spectra collected from colloidal batches 2 and 3 generated
no spectral features when combined with salts 1.0 M KNO3
and 0.5 M KNO3 respectively, repeat collections of the spectral
data sets also proved unsuccessful, so these systems were
omitted from further analysis. To interpret the optimum aggre-
gation time for the systems, plots of peak area vs. time (s) were
generated for each identified peak and manually assessed,
with the objective of verifying the time at which the SERS
signal reached a plateau. The time which was identified at the
centre of the plateau region was designated as the optimum
aggregation period. Identified times were then averaged across
all the peaks identified in the individual systems. To generate
values for peak area trapezoidal integration was used. This
method splits the area under a peak into multiple trapezoidal
components, from which the individual areas are calculated
then summed giving an overall area value between the speci-
fied minima of a single peak. An example aggregation plot,
demonstrating the position of the plateau region can be seen
in Fig. 4 together with a table summarising the optimum
aggregation times for all the colloidal batch variations.
Reproducibility studies
To study the reproducibility of SERS signal 5 replicates of each
SERS system were used. In addition to the 40 min lag phase,
each of the systems were allowed to aggregate for the defined
optimum aggregation period after the salt solution was intro-
duced. Spectra were analysed in a similar way as described pre-
viously except this time the relative standard deviations (RSDs)
of each peak area were calculated and used to assess reprodu-
cibility between the diﬀerent batches of sol. All peaks with a
RSD <15% were deemed reproducible and were tallied for each
system. As the number of peaks present in the spectra of each
of the systems appeared to vary quite significantly, the number
of peaks <15% were calculated as a percentage of the total
number of peaks visible. One reason for the presence of so
many diﬀerent peaks in the spectra and the inability to assign
them all to MDAI is due to the dynamic nature of the solution
phase system. As the citrate stabilised nanoparticles are mixed
Fig. 3 Average scaled spectra of each batch of colloid generated through the optimisation of aggregation experiment. (A) Represents spectra col-
lected using 0.5 M aggregating agent (KNO3) and (B) represents spectra collected using 1 M aggregating agent (KNO3). Each spectrum was taken in
the presence of 500 ppm (2.8 × 10−3 M) MDAI.
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into a solution of MDAI, the citrate and MDAI undergo rapid
exchange on the surface. It is expected that MDAI would have
a higher aﬃnity for the silver due to it containing an amine
group, therefore it is also expected that greater numbers of
MDAI will eventually reside on the nanoparticles, than citrate.
However, it must be remembered that neither citrate nor MDAI
molecules are covalently bound to the nanoparticles, but
instead are loosely associated; this ‘association’ along with the
dynamic exchange also means that the orientation of the mole-
cules on the surface is constantly changing. One advantage of
carrying out these experiments in solution is the averaging
eﬀects achieved from Brownian motion and a large laser
sampling volume; however, this does not mean that the indi-
vidual systems will display exactly the same numbers of spec-
tral features. Table 1 shows the results of the reproducibility
testing and it is evident that colloidal batch 1 with 0.5 M and
1.0 M KNO3 demonstrates the best reproducibility of all the
batches with 71% and 69% of the peaks present displaying
RSDs of <15%. Colloidal batch 4 combined with 1.0 M of salt
can be seen to have the worst reproducibility with only 1 peak
in 16 having an RSD less than 15%. Therefore the system
which consisted of Batch 1 and 0.5 M salt was used to estab-
lish the LOD of MDAI. Although it was initially thought that
higher concentrations of KNO3 would hasten the aggregation
time and eﬀect reproducibility in some way, from this study no
conclusions could be drawn as the eﬀect this increase has on
Fig. 4 An example plot of peak area versus time for the determination of optimum aggregation time. The plot was generated using the peak area at
1609 cm−1 using colloidal batch 1 and 0.5 M KNO3. The red line outlines the plateau region where the standard deviation relating to peak area is at
its minimum. The time at the centre of this plateau region is estimated to be 1800 s or 30 min, this is deﬁned as the optimum aggregation time opti-
mised aggregation times are detailed in the adjoining table for the diﬀerent colloidal batches and respective salt concentrations.
Table 1 The reproducibility of the peaks present in each of the systems
is assessed to ﬁnd the best system. RSDs are assessed using the peak
areas calculated for every single peak present in the 5 replicate spectra
collected. Peaks with an RSD <15 were deemed acceptable
Peaks present in spectra
Colloidal batch no KNO3 (M) Total no
No with
RSD <15
% of peaks
with RSD <15
1 0.5 14 10 71
1 1 13 9 69
2 0.5 14 4 29
3 1 16 5 31
4 0.5 12 7 58
4 1 16 1 6
5 0.5 18 6 33
5 1 16 8 50
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the overall MDAI signal. The levels of variation in SERS signal
seen with the diﬀering batches of colloid are due to the diﬀer-
ence in size and distribution of the synthesised nanoparticles.
Work carried out previously within the group highlighted the
variability of colloidal batches and in doing so also empha-
sised the need for careful assessment of the nanoparticles.25
Limit of detection (LOD) studies
When the concentration of MDAI was lowered it became
evident which seven peaks in the spectra were representative
of the analyte. Fig. 5 shows a mean blank spectrum (200 μL of
colloidal batch 1, 200 μL of water and 50 μL of 0.5 M KNO3)
overlaid with a 500 ppm SERS spectrum of MDAI (200 μL of
colloidal batch 1, 200 μL of 500 ppm MDAI and 50 μL of 0.5 M
KNO3). The red bands highlight the peaks in the plot from
which the LOD of MDAI was established. Table 2 shows the
LOD and band assignments for each of the peaks analysed.
The LOD was estimated using the baseline corrected peak
intensities at each concentration and by applying eqn (1).
Where SD is the standard deviation of the colloidal blank,
c the intercept and m the gradient. The SD of the colloidal
blank was estimated using the same peak positions and inten-
sities used when MDAI was present.
LOD ¼
ðð3 SD of blankÞ+ cÞ
m
ð1Þ
The LODs calculated for the 7 peaks identified ranged from
∼20 to 6 ppm (1.42 × 10−5 M to 3.19 × 10−4 M). The average
LOD estimated from all the peaks was 8 ppm (5.4 × 10−5 M).
Example LOD plots are displayed in Fig. 6. Fig. S2† shows
mean spectra collected at each MDAI concentration down to
the LOD (including a colloidal blank).
Conclusion
In this study it has been demonstrated that SERS can be used
to detect the presence of MDAI in solutions at concentrations
lower than previously reported methods of 200 ppm by micro-
crystalline testing.18 It has also been shown that signal vari-
Fig. 5 The plot shows a scaled overlay of SERS spectra for the optimised blank colloidal system in blue (colloidal batch 1, 0.5 M KNO3 and no MDAI)
with the optimised colloidal system containing MDAI in red (colloidal batch 1, 0.5 M KNO3, and 500 ppm MDAI). The peaks used for the LOD studies
are highlighted by the red bands numbered 1–7. The peaks are positioned at 456 cm−1, 565 cm−1, 715 cm−1, 1190 cm−1, 1353 cm−1, 1459 cm−1 and
1609 cm−1. At low concentrations of MDAI, the citrate peaks from ∼1100–1650 cm−1 appear more prevalent making it diﬃcult to assign the MDAI
peaks in this region.
Table 2 Tentative SERS vibrational assignments for the 7 peaks identiﬁ-
ed for MDAI
Peak position
(cm−1) Assignment
Estimated LOD
(M)
456 Unassigned 3.30 × 10−5
565 Unassigned 3.19 × 10−5
715 Substituted benzene
deformation
3.80 × 10−5
1190 C–N stretch or dioxolane ring
vibration
1.42 × 10−4
1353 Unassigned 4.53 × 10−5
1459 1,2,4,5-tetrasubstituted benzene
vibration
5.31 × 10−5
1609 CvC aromatic stretch 3.75 × 10−5
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ations can occur between diﬀerent batches of silver sol syn-
thesised using the same preparative methods, and this empha-
sises the need for optimisation in order to improve signal
reproducibility. A technique’s reproducibility and sensitivity
ultimately influences its widespread usage in the analytical
field, so optimisations like the ones carried out here are
important. The optimised SERS method was also demon-
strated to be clearly quantitative and the typical limit of detec-
tion for MDAI was 5.4 × 10−5 M. Overall a cheap, facile,
sensitive and reproducible method for the detection of a sub-
stance has been produced. Moreover, due to the ready portabil-
ity of Raman spectroscopy and SERS this approach could be
deployed in the field. Further work would involve the evalu-
ation of the discriminatory properties of such an optimised
system, which we have previously reported for other drugs con-
taining the same structural moieties using chemometric
methods.26
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